Parkinson's disease (PD) is a neurodegenerative disorder that primarily affects the dopaminergic neurons in the substantia nigra, leading to motor and non-motor symptoms. As healthcare professionals, understanding the complexities of PD is crucial in providing optimal patient care.
The etiology of PD is multifactorial, involving both genetic and environmental factors. Pathologically, PD is characterized by the accumulation of alpha-synuclein, forming Lewy bodies, and the loss of dopaminergic neurons in the substantia nigra. These changes lead to a decrease in dopamine levels, which is responsible for the motor symptoms observed in PD.
PD presents with both motor and non-motor symptoms. The cardinal motor symptoms are rest tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms include autonomic dysfunction, sleep disorders, cognitive impairment, and depression. These symptoms can significantly impact the quality of life of patients.
Diagnosis of PD is primarily clinical, based on the presence of the cardinal motor symptoms and response to dopaminergic therapy. Neuroimaging techniques and biomarkers can aid in the diagnosis, but they are not definitive. Early diagnosis and management are key to improving patient outcomes.
The mainstay of treatment for PD is pharmacological therapy aimed at increasing dopamine levels or mimicking its effects. Non-pharmacological interventions such as physiotherapy and occupational therapy also play a crucial role in managing the symptoms and improving quality of life.
PD is a complex neurodegenerative disorder with a multifactorial etiology and diverse clinical presentation. As healthcare professionals, our understanding and management of PD need to be comprehensive and patient-centered, focusing not only on the motor symptoms but also on the non-motor symptoms that significantly impact patients' quality of life.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation